Clinical Trial Update: A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma [Phase 1]

View source ↗

Summary

Phase I, open-label, ascending-dose trial of SPI-1620 (Endothelin B agonist) assessing safety, tolerability, pharmacokinetics and pharmacodynamics in patients w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma

Drugs mentioned

• SPI-1620 (SPI-1620)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Carcinoma | Phase 1 | Status: COMPLETED